Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Blood

• Publication date

  2016-07-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2016-01-694356PMID 27166358PMCID PMC4957161
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

  2015cited by this paper
• Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

  2015cited by this paper
• Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.

  2015cited by this paper
• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

  2015influential reference
• The generation of antibody-secreting plasma cells

  2015cited by this paper
• A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow.

  2015influential reference
• Monoclonal antibodies in acute lymphoblastic leukemia.

  2015cited by this paper
• The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014influential reference
• Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers.

  2014cited by this paper
• Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

  2014cited by this paper
• Robust isolation of malignant plasma cells in multiple myeloma.

  2014cited by this paper
• Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.

  2014cited by this paper
• CD19-CAR Trials

  2014cited by this paper
• A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function

  2013cited by this paper
• B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.

  2013cited by this paper
• Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2013cited by this paper
• Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination

  2013cited by this paper
• B-cell selection and the development of autoantibodies

  2012cited by this paper
• Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma

  2012cited by this paper
• Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity

  2012cited by this paper
• Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity

  2012cited by this paper
• Effect of rituximab on human in vivo antibody immune responses.

  2011cited by this paper
• Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Steady state generation of mucosal IgA+ plasmablasts is not abrogated by B cell depletion therapy with rituximab

  2010cited by this paper
• Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

  2009cited by this paper
• Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice1

  2008cited by this paper
• Maintenance of the plasma cell pool is independent of memory B cells

  2008cited by this paper
• Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.

  2008cited by this paper
• B Cell Survival in Intragraft Tertiary Lymphoid Organs After Rituximab Therapy

  2008cited by this paper
• Duration of humoral immunity to common viral and vaccine antigens.

  2007cited by this paper
• Quantitative analysis of herpes simplex virus type 1-specific memory B cells generated by different routes of infection.

  2007cited by this paper
• Pharmacodynamics of Rituximab in Kidney Allotransplantation

  2006cited by this paper
• Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices

  2006cited by this paper
• Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

  2005cited by this paper
• Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody

  2005cited by this paper
• Plasma Cell Ontogeny Defined by Quantitative Changes in Blimp-1 Expression

  2004influential reference
• Levels of Antibodies Specific to Tetanus Toxoid, Haemophilus influenzae Type b, and Pneumococcal Capsular Polysaccharide in Healthy Children and Adults

  2003influential reference
• Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

  1998cited by this paper
• Humoral immunity due to long-lived plasma cells.

  1998cited by this paper
• Lifetime of plasma cells in the bone marrow

  1997influential reference
• Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry.

  1990cited by this paper
• Persistence of serum IgA antibodies to herpes simplex, varicella‐zoster, cytomegalovirus, and rubella virus detected by enzyme‐linked immunosorbent assays

  1985cited by this paper
• AN AUTORADIOGRAPHIC STUDY OF THE STABILITY OF PLASMA CELL RIBONUCLEIC ACID IN RATS.

  1964influential reference

• Plasmablast, memory B cell and T follicular helper cell responses after human papillomavirus vaccination: effect of dose number and age.

  2026cites this paper
• Impact of CD19 CAR T-Cell Therapy on Pathogen-Specific Antibody Titers in Lymphoma Patients.

  2026cites this paper
• Clinical progress of engineered cellular immunotherapies for autoimmunity.

  2026cites this paper
• Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.

  2026cites this paper
• Expert Consensus on Cytomegalovirus Management in Recipients of CAR-T Cell and Bispecific Antibody Therapies.

  2026cites this paper
• Evaluation of Preexisting Humoral Immunity to Measles and Varicella Zoster in Patients With Multiple Sclerosis Initiating Anti-CD20 Therapy

  2026cites this paper
• Hypogammaglobulinemia at leukapheresis predicts delayed humoral immune reconstitution and increased risk of infections after CD19 CAR-T for B-cell lymphoma.

  2026cites this paper
• Human Atypical B Cells. An Overview

  2025cites this paper
• A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies

  2025cites this paper
• Impacts of ageing on the efficacy of CAR-T cell therapy.

  2025cites this paper
• CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon

  2025cites this paper
• CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease

  2025cites this paper
• Clinical opinions and case studies on understanding and managing hypogammaglobulinaemia in multiple sclerosis: United Kingdom perspective.

  2025cites this paper
• Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?

  2025cites this paper
• Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia

  2025cites this paper
• HLA-Fc fusion proteins for antigen-specific humoral suppression.

  2025cites this paper
• Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases

  2025cites this paper
• Noncanonical and mortality-defining toxicities of CAR T cell therapy

  2025cites this paper
• Use of CD19-targeted Immune Modulation to Eradicate AAV Neutralizing Antibodies.

  2025cites this paper
• Can autoimmune disease be cured by deep CD19+ cell depletion?

  2025cites this paper
• CAR T-cell therapy for neurological disorders: scientific rationale and mechanistic insights

  2025cites this paper
• Leveraging T cells for cancer immunotherapy

  2025cites this paper
• Can we cure autoimmunity?

  2025cites this paper
• Haemophagocytic lymphohistiocytosis (HLH) secondary to measles in an adult with a loss of post-vaccination humoral immunity following rituximab.

  2025cites this paper
• B cell depletion as a therapeutic strategy for neuromyelitis optica spectrum disorder: rationale, evidence, and challenges

  2025cites this paper
• Hypoimmune CD19 CAR T cells treat allogeneic mice with features of spontaneous systemic lupus erythematosus

  2025cites this paper
• CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?

  2025cites this paper
• ANTIBODY TITERS OF VACCINE-PREVENTABLE PATHOGENS AT ONE YEAR POST CD19 CAR-T CELL THERAPY.

  2025cites this paper
• Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a case report

  2025cites this paper
• Effective Use of BCMA-Targeting Bispecific T-Cell-Engaging Antibody in Treatment Refractory LRP4-positive Myasthenia Gravis.

  2025cites this paper
• Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

  2024cites this paper
• Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing.

  2024cites this paper
• Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions.

  2024cites this paper
• Chimeric antigen receptor T cell therapy for autoimmune disease

  2024cites this paper
• Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection.

  2024cites this paper
• CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types

  2024cites this paper
• Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?

  2024cites this paper
• A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells

  2024cites this paper
• Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity

  2024cites this paper
• Chimeric antigen receptor T cells in the fast lane among autoimmune disease therapies

  2024cites this paper
• Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease

  2024cites this paper
• Serial Evaluation of Pre-immunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy.

  2024cites this paper
• From neglect to spotlight: the underappreciated role of B cells in cutaneous inflammatory diseases

  2024cites this paper
• In vivo tracking of ex vivo generated 89Zr-oxine labeled plasma cells by PET in a non-human primate model.

  2024cites this paper
• Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy

  2024influential citation
• CAR T-cells in autoimmunity: game changer or stepping stone?

  2024cites this paper
• B-cell targeted therapies in autoimmune encephalitis: mechanisms, clinical applications, and therapeutic potential

  2024cites this paper
• Survivorship in Chimeric Antigen Receptor T-Cell Therapy Recipients: Infections, Secondary Malignancies, and Non-Relapse Mortality

  2024cites this paper
• Recruitment of plasma cells from IL-21-dependent and IL-21-independent immune reactions to the bone marrow

  2024cites this paper
• Fibroblast‐like synoviocytes preferentially induce terminal differentiation of IgD+ memory B cells instead of naïve B cells

  2024cites this paper
• Current understanding and management of CAR T cell-associated toxicities

  2024cites this paper
• Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity.

  2024cites this paper
• Cars pick up another passenger: Organ transplantation.

  2024cites this paper
• Chimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections

  2024cites this paper
• CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases

  2024cites this paper
• From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases

  2024cites this paper
• CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.

  2024cites this paper
• Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept

  2024cites this paper
• Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial

  2024cites this paper
• The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19.

  2024cites this paper
• Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy

  2024cites this paper
• Targeting pathogenic CD8+ tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis

  2024cites this paper
• IgG replacement in multiple myeloma

  2024cites this paper
• Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities

  2024cites this paper
• CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview

  2024cites this paper
• Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice.

  2024cites this paper
• Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature

  2023cites this paper
• B cells and antibodies in refractory immune thrombocytopenia

  2023cites this paper
• Targeting plasma cells in systemic autoimmune rheumatic diseases - promises and pitfalls.

  2023cites this paper
• Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy

  2023cites this paper
• Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention

  2023cites this paper
• Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms.

  2023cites this paper
• Chimeric antigen receptor T cell therapy for the treatment of systemic rheumatic diseases: a comprehensive review of recent literature

  2023cites this paper
• Chimeric antigen receptor T cells therapy in solid tumors

  2023cites this paper
• Unveiling the autoreactome: Proteome-wide immunological fingerprints reveal the promise of plasma cell depleting therapy

  2023cites this paper
• CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus

  2023cites this paper
• Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies

  2023cites this paper
• Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies

  2023cites this paper
• The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases.

  2023cites this paper
• The role of B-cell ferroptosis in the pathogenesis of systemic lupus erythematosus.

  2023cites this paper
• Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing

  2023cites this paper
• Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy

  2023cites this paper
• Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy

  2023cites this paper
• Mathematical modeling of heterogeneous stem cell regeneration: from cell division to Waddington's epigenetic landscape

  2023cites this paper
• Vaccinations in children with hematologic malignancies and those receiving hematopoietic stem cell transplants or cellular therapies

  2023cites this paper
• Long‐term survivorship care after CAR‐T cell therapy

  2023cites this paper
• Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management

  2023influential citation
• Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

  2023cites this paper
• Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy

  2023cites this paper
• SARS-CoV-2 specific plasma cells acquire long-lived phenotypes in human bone marrow

  2023cites this paper
• Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches

  2023cites this paper
• Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology.

  2022cites this paper
• Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy.

  2022cites this paper
• CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs

  2022cites this paper
• Therapeutic Opportunities for Immunoreceptor-Engineered T Cell Therapy for Modulation of Alloimmunity

  2022cites this paper
• Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept

  2022cites this paper
• SARS-CoV-2 specific plasma cells acquire the phenotype of long-lived plasma cells in the human bone marrow

  2022cites this paper
• Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy

  2022cites this paper
• Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy

  2022cites this paper
• CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation

  2022cites this paper